Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BLS Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was €0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €4.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals EV-to-EBIT Related Terms
BLS Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's EV-to-EBIT falls into.
BLS Pharmaceuticals's current Enterprise Value is €133.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €4.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (FRA:PR80) has a EV-to-EBIT of 29.05 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #252 out of 372 companies in the Biotechnology industry, placing it in the top 67.7%.
Is BLS Pharmaceuticals' EV-to-EBIT too high?
BLS Pharmaceuticals' current EV-to-EBIT is 29.05. The Biotechnology industry median EV-to-EBIT is 13.35. BLS Pharmaceuticals' value of 29.05 is 117.6% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #252 out of 372 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' EV-to-EBIT compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #252 out of 372 companies for EV-to-EBIT. This places BLS Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 13.35. BLS Pharmaceuticals' value of 29.05 is 117.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current EV-to-EBIT of 29.05 is 117.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current EV-to-EBIT is 29.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €0.56 — trading 40.3% above its estimated fair value. The current EV-to-EBIT is 29.05 and 117.6% above the Biotechnology industry median of 13.35. BLS Pharmaceuticals' overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current EV-to-EBIT is 29.05 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.56 is trading 40.3% above its estimated GF Value™ of €0.40.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
EV-to-EBIT: 29.05
GF Value™: €0.40 vs. price of €0.56 (40.3% above fair value)
Industry Position: 117.6% above the Biotechnology median (#252 of 372)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
38GF Score
Get the complete analysis for FRA:PR80
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
